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Objective:  Exogenous  insulin  use  in  patients  with  type  2  diabetes  (DM2)  has  been associated  with  an
increased  risk  of  cardiovascular  events.  Through  which  mechanisms  insulin  may  increase  atherosclerotic
plaque  vulnerability  is  currently  unclear.  Because  insulin  has been  suggested  to  promote  angiogenesis  in
diabetic  retinopathy  and  tumors,  we  hypothesized  that insulin  enhances  intra-plaque  angiogenesis.
Methods: An  in vitro  model  of pathological  angiogenesis  was  used  to  assess  the  potential  of  insulin
to  enhance  capillary-like  tube  formation  of human  microvascular  endothelial  cells  (hMVEC)  into  a
three  dimensional  ﬁbrin  matrix.  In  addition,  insulin  receptor  expression  within  atherosclerotic  plaques
was  visualized  in carotid  endarterectomy  specimens  of 20  patients  with  carotid artery  stenosis,  using
immunohistochemical  techniques.  Furthermore,  microvessel  density  within  atherosclerotic  plaques  was
compared  between  68  DM2 patients  who  received  insulin  therapy  and  97 DM2 patients  who  had  been
treated  with  oral  glucose  lowering  agents  only.
Results: Insulin,  at a concentration  of  10−8 M,  increased  capillary-like  tube formation  of  hMVEC  1.7-fold
(p  <  0.01).  Within  human  atherosclerotic  plaques,  we observed  a speciﬁc  distribution  pattern  for  the
insulin  receptor:  insulin  receptor  expression  was  consistently  higher  on  the  endothelial  lining  of  small
nascent  microvessels  compared  to more  mature  microvessels.  There  was  a  trend  towards  an  increased
microvessel  density  by 20%  in atherosclerotic  plaques  derived  from  patients  using  insulin  compared  to
plaques  derived  from  patients  using  oral  glucose  lowering  agents  only  (p  =  0.05).
Conclusion:  Exogenous  insulin  use  in  DM2  patients  may  contribute  to increased  plaque  vulnerability  by
nesisstimulating  local  angiogeAbbreviations: 3D, three-dimensional; ATHERO-EXPRESS, ATHEROsclerotic
laque  EXPRESSion; bFGF, basic ﬁbroblast growth factor; DM2, type 2 diabetes melli-
us; ECGF, endothelial cell growth factor; hMVEC, human microvascular endothelial
ells;  HuSi, heat-inactivated human serum; IR, insulin receptor; NBCSi, heat-
nactivated newborn calf serum; SMA, smooth muscle cell actin; SMC, smooth
uscle  cell; TNF-, tumor necrosis factor alpha.
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1. Introduction
Administration of exogenous insulin has signiﬁcantly improved
life expectancy in patients with diabetes. However, epidemiologic
surveys have recently suggested that insulin may  also increase the
risk of cardiovascular events. A post hoc analysis of the DIGAMI
2 trial revealed that chronic insulin use in patients with diabetes
mellitus type 2 (DM2), who survived a myocardial infarction, is
associated with increased risk of re-infarction or stroke [1]. Sim-
ilarly, other studies within large administrative databases also
Open access under the Elsevier OA license.indicated that insulin use is associated with an increased cardiovas-
cular event rate [2–4]. Moreover, increasing dosages of exogenous
insulin seem to have an incremental impact on cardiovascular
mortality: the higher the cumulative insulin exposure, the higher
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he risk of dying from cardiovascular disease [5].  Mechanisti-
ally, the adverse effects of insulin on cardiovascular outcome
ave been attributed to adverse actions of insulin on the ves-
el wall, comprising increased adhesion molecule expression on
ndothelial cells, increased transendothelial migration of leuko-
ytes [6,7], stimulation of smooth muscle cell (SMC) proliferation
8,9], and pro-inﬂammatory effects [10]. If additional mechanisms
s to how insulin can increase plaque vulnerability are elucidated,
t might become easier to distinguish between patients in whom
igh insulin doses will increase plaque vulnerability and patients
n whom insulin treatment is safe with respect to progression of
therosclerosis.
Angiogenesis within atherosclerotic plaques is involved in pro-
ression of atherosclerosis [11]. The ﬁrst steps of intra-plaque
ngiogenesis are characterized by migration and proliferation
f endothelial cells from pre-existing microvessels. This process
esults in the formation of a new lumen and is also referred to as
apillary-like tube formation. Subsequently, these newly formed
apillaries mature into microvessels. Due to disturbed functional-
ty of the endothelial lining of these intra-plaque microvessels, high
icrovessel density predisposes to an increased risk of intra-plaque
emorrhage and plaque rupture [12,13]. In earlier studies, insulin
as been suggested to promote angiogenesis in diabetic retinopa-
hy and tumors [14–16].  However, whether insulin contributes to
ngiogenesis within atherosclerotic plaques is currently unknown.
In the present study, we hypothesized that insulin enhances
ntra-plaque angiogenesis. Speciﬁcally, we aimed to answer the
ollowing questions: (1) Does in vitro stimulation of human
icrovascular endothelial cells with insulin enhance capillary-like
ube formation? (2) Are insulin receptors (IRs) present on endothe-
ial cells within human atherosclerotic plaques? (3) Is microvessel
ensity within atherosclerotic plaques higher in patients with DM2
sing insulin than in those using oral glucose lowering agents only?
. Materials and methods
.1. In vitro angiogenic sprouting assay
.1.1. Cell culture
Human microvascular endothelial cells (hMVEC) from fore-
kin were isolated, cultured and characterized as previously
escribed by van Hinsbergh et al. [17]. hMVEC were cultured in
edium 199 supplemented with 10% (v/v) heat-inactivated human
erum (HuSi), 10% (v/v) heat-inactivated newborn calf serum
NBCSi), 100 IU/ml penicillin, 100 g/ml streptomycin (pen/strep),
.75 g/ml endothelial cell growth factor (ECGF, crude extract from
ovine brain), 5 IU/ml heparin and 2 mM l-glutamine. Conﬂuent
ells were washed, trypsinized (0.05% trypsin) and seeded at 1:3
ensity. Cells were cultured on 1% gelatin coated plates at 37 ◦C in
 water-saturated atmosphere of 95% air and 5% CO2. hMVEC were
sed until passage 10. The use of hMVEC was approved by the eth-
cal committee of the VU University Medical Center, Amsterdam,
he Netherlands.
.1.2. Capillary-like tube formation of hMVEC
Human ﬁbrin matrices were prepared with 2 mg/ml ﬁbrinogen
Calbiochem, La Jolla, CA, USA) and 0.1 U/ml thrombin (Organon,
oxtel, the Netherlands) in Medium 199 containing pen/strep.
00 l mixture was added to the wells of 96-well plates. After
lotting at 37 ◦C, the ﬁbrin matrices were soaked with Medium
99 supplemented with pen/strep, 10% HuSi, 10% NBCSi and 2 mM
-glutamine for 16 h at 37 ◦C to inactivate thrombin. Conﬂuent
MVEC were seeded on the ﬁbrin matrices. Six hours after seed-
ng, the cells were stimulated in serum containing M199 with the
ombination of 10 ng/ml basic ﬁbroblast growth factor (bFGF) andsis 222 (2012) 208– 215 209
10 ng/ml tumor necrosis factor alpha (TNF-; Sigma Aldrich, St
Louis, MO,  USA) with or without insulin (bovine, Sigma Aldrich,
St Louis, MO,  USA) (10−9–10−7 M).  Every second day, the medium
was  removed and replaced by fresh stimulation medium. Within all
experiments each condition was studied in triplicate. After 7–9 days
the formation of tubular structures was  analyzed by phase-contrast
microscopy [18] and total tube length of structures of four ran-
domly chosen microscopic ﬁelds was measured using a Q-imaging
camera connected to a computer with Optimas image analysis soft-
ware (Media Cybernetics, Bethesda, MD,  USA), and expressed as
mm/cm2.
2.2. Insulin receptor expression on microvessels within
atherosclerotic plaques
2.2.1. Tissue samples
In order to assess IR expression in atherosclerotic plaques we
randomly selected 20 human carotid endarterectomy specimens
from the vascular tissue bank of the Academic Medical Center, Ams-
terdam, which contains systematically collected surgical resection
specimen of arteries and veins from patients with peripheral-,
aortic- and carotid artery disease. For this study we used carotid
endarterectomy specimens containing atherosclerotic plaques that
had been routinely ﬁxed in buffered formalin and were embed-
ded in parafﬁn. Insulin receptor expression within the plaques was
examined by single and double immunoenzyme staining. Collagen
IV expression was  assessed in carotid endarterctomy specimen of
6 patients.
2.2.2. Single immunohistochemistry for IR and IGF-1 receptor
Parafﬁn tissue sections of 4 m thickness were dewaxed in
xylene and re-hydrated via graded alcohols. Endogenous peroxi-
dase activity was blocked with methanol + 0.3% peroxide (20 min,
room temperature). Heat-induced epitope retrieval (HIER) for tis-
sue pretreatment was applied using Tris–EDTA pH 9.0 (20 min
at 98 ◦C) in a Pretreatment Module (Thermo/LabVision, Fre-
mont, CA). For single stainings we used IR antibody (Clone CT-3,
1 g/ml, 60 min  incubation at room temperature) and IGF-1 recep-
tor antibody (clone Rb IgG, 0.25 g/ml, overnight incubation at
4 ◦C). Both antibodies were purchased from Millipore/Chemicon,
Temecula, CA, USA. A three-step polymer detection system was
applied (ImmunoLogic, Duiven, the Netherlands), using a post
antibody blocking step (15 min, room temp.) followed by an
anti-rabbit/mouse/rat horseradish peroxidase (HRP)-conjugated
polymer. HRP activity was visualized in brown using Bright DAB
(ImmunoLogic). Negative controls consisted of concentration-
matched isotype controls (Dako).
2.2.3. Double Immunohistochemistry
Immuno double staining combining IR antibody in red with
SMA, CD31, CD3 or CD68 antibodies in blue was  performed with
the sequential double alkaline phosphatase (AP) method as pre-
viously described and summarized in Supplemental Table 1 [19].
In brief: immunostaining started with the detection of SMA,
CD31, CD3 or CD68 antibody with an appropriate Bright Vision
anti-mouse or anti-rabbit alkaline phosphatase (AP)-conjugated
polymer (ImmunoLogic, Duiven, the Netherlands). AP activity was
visualized in blue using Vector Blue (Vector Labs, Burlingame, CA).
To abolish cross-reaction between ﬁrst and second primary mouse
antibodies, a 10 min  heat step (98 ◦C) was  performed in between,
using Tris–EDTA pH 9.0 to remove the ﬁrst set of immunoreagents,
but leaving the blue AP reaction product unchanged. IR mouse anti-
body was next detected with anti-mouse AP-conjugated polymer
and visualized in red using Vector Red (Vector Labs). No nuclear
counterstain was  applied.
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Immuno double staining combining IR antibody in brown with
ollagen IV or CD34 antibodies in red was performed as described
n Supplemental Table 1. First, IR antibody was  detected with
 Bright Vision anti-mouse HRP-conjugated polymer and visual-
zed with Bright DAB. Secondly, after a heat-step, CD34 antibody
as detected with Bright Vision anti-mouse AP-conjugated poly-
er  and visualized in red using Vector Red. Collagen type IV
ntibody required pepsin digestion treatment after this second
eat-step (Supplemental Table 1). The DAB reaction product at
he end of the ﬁrst staining sequence ensures effective shielding,
reventing cross-reaction of the collagen type IV antibody and sub-
equent Bright Vision anti-mouse AP-conjugated polymer with the
rst staining sequence [20,21]. A weak hematoxylin (1:10 diluted,
 min) nuclear counterstain was applied. Controls consisted of
alf-double staining experiments, omitting one of the primary anti-
odies.
All sections were organically mounted with VectaMount (Vec-
or).
.2.4. Spectral imaging
Double staining slides were analyzed with the Nuance spec-
ral imaging system (Caliper Life Sciences/Cambridge Research
nstrumentation, Woburn, MA,  USA). Spectral imaging data cubes
ere taken from 420 to 720 nm at 20 nm intervals and analyzed
ith the NuanceTM 2.8 software. Spectral libraries of single-brown
DAB), single-red (Vector Red), single-blue (Vector Blue), and
ingle-hematoxylin were obtained from the control slides. The
esulting library was applied to the double stained slides for spec-
ral unmixing into individual component images, representing the
ocalization of each of the reaction products [22]. Fluorescent-like
mages composed of pseudo-colors showing co-localization, as well
s an exclusive image of co-localization, were created with the
uance 3.0 software.
. Microvessel density within atherosclerotic plaques
In order to compare microvessel density in atheroscle-
otic plaques from DM2  patients on insulin therapy with
laques from DM2  patients without insulin therapy we selected
uman endarterectomy specimens from the ATHERO-EXPRESS
ATHEROsclerotic plaque EXPRESSion) study [23]. This is an ongo-
ng longitudinal multicenter study in the Netherlands which
nrolls patients undergoing carotid endarterectomy. All patients
ndergoing carotid endarterectomy in the participating centers
St. Antonius Hospital Nieuwegein and University Medical Center
trecht) were considered eligible for inclusion. The medical ethics
oard of the participating hospitals approved the study and all
articipants provided written informed consent. The deﬁnition of
iabetes was restricted to those cases requiring medical treatment
23]. We  analyzed 165 patients with carotid artery stenosis and
oncomitant DM2. Sixty-eight of them had been on insulin therapy
nd 97 had not been on insulin therapy. Plaque characteristics were
etermined as previously described [24]. For semi-quantitative
nalyses of collagen, macrophage, SMC  and calciﬁcation content,
wo categories were made (no/minor and moderate/heavy).
All sections were stained for CD34 using a mouse anti-CD34
onoclonal antibody (1 g/ml; Immunotech, Marseille, France)
s primary antibody. Subsequently, sections were stained with
owervision poly AP-anti-mouse IgG (ImmunoLogic, Duiven, the
etherlands), developed in New Fuchsin Alkaline Phosphatase
ubstrate and counterstained with hematoxylin. Using a mag-
iﬁcation of 400×, CD34-positive microvessels were counted in
hree areas of the plaque with the highest microvessel density (so
alled hotspots). Subsequently, the average microvessel density per
otspot was calculated for each plaque [25].sis 222 (2012) 208– 215
3.1. Statistical analysis
Data of in vitro experiments are presented as mean ± SEM.
Statistical differences in capillary-like tube formation were deter-
mined by paired t-test, using Prism 4 (GraphPad, San Diego,
CA, USA). Patients’ and plaque characteristics are presented as
mean ± SD (for normally distributed parameters), median (IQR) (for
not-normally distributed parameters), or as percentage. Statistical
differences between groups for normally distributed continuous
variables were calculated using an unpaired t-test. For not-
normally distributed parameters Mann–Whitney’s U test and for
categorical data a 2-test were used. Data were analyzed using SPSS
16.0 for Windows (SPSS Inc., Chicago, IL). p values below 0.05 were
considered statistically signiﬁcant.
4. Results
4.1. In vitro angiogenic sprouting assay
4.1.1. Insulin enhances capillary-like endothelial tube formation
To determine whether insulin has a stimulatory effect on the
formation of microvessels, we  used an in vitro angiogenesis assay.
Human microvascular endothelial cells (hMVEC) seeded on a 3D
ﬁbrin matrix were stimulated with bFGF and TNF- for 7–9 days to
induce capillary-like tube formation. Addition of insulin (in a range
of 10−9–10−7 M)  to the medium increased capillary-like endothe-
lial tube formation dose dependently (Fig. 1A and B). Insulin alone
did not induce capillary-like tube formation. Combining the results
of 11 separate experiments (using 3 different hMVEC donors)
revealed that stimulating with 10−8 M insulin combined with bFGF
and TNF- signiﬁcantly increased capillary-like tube formation 1.7-
fold compared to stimulation with bFGF and TNF- alone (Fig. 1C).
4.2. Insulin receptor expression on microvessels within
atherosclerotic plaques
4.2.1. Increased insulin receptor expression on small microvessels
within human atherosclerotic plaques
In total we studied IR expression in 20 carotid endarterec-
tomy specimens containing atherosclerotic plaques (stages III–VI,
according to the American Heart Association classiﬁcation). All
sections showed positive staining for IRs, especially on microves-
sels within the plaque. More in detail, we  found a speciﬁc
distribution pattern with regard to IR expression, consisting of
increased expression on small microvessels compared with larger
microvessels (Fig. 2). These IR positive microvessels were located
predominantly at the border between the media and the lipid core,
or in the lipid core. Additional stainings for insulin like growth fac-
tor (IGF)-1 receptors did not reveal such a distribution pattern on
microvessels as observed for the IR. IGF-1 receptors were expressed
both on small and large microvessels and also on other cell types
within atherosclerotic plaques (data not shown).
4.2.2. Insulin receptors co-localize with endothelial cells on small
microvessels
To assess whether IRs were indeed present on endothelial
cells of microvessels, double immuno-staining was performed.
We found a marked co-localization of IRs with CD31 positive
(endothelial) cells, especially on small microvessels (Fig. 3B and
C). Co-localization of IRs with other components within the
atherosclerotic plaque was less evident. Macrophages (character-
ized by CD68) showed focal, minimal IR expression, whereas T-cells
(characterized by CD3) showed no IR expression. Immuno-enzyme
staining for IRs and smooth muscle actin (SMA) revealed a variable
expression of IRs on smooth muscle actin positive cells; insulin
receptors were predominantly present on myoﬁbroblastic cells
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Fig. 1. In vitro angiogenic sprouting assay. hMVEC were cultured on top of a 3D ﬁbrin matrix in M199 supplemented with 10% human serum and 10% NBCSi. Capillary-like tube
formation was  induced by stimulating hMVEC with 10 ng/ml TNF- and 10 ng/ml bFGF alone (control) or in combination with different doses of insulin. (A) Representative
phase  contrast pictures after 7 days of culture showing increased capillary-like tube formation in the presence of insulin. Scale bar is 0.5 mm.  (B and C) Capillary-like tube
formation quantiﬁed with Optimas software. (B) Results of a single experiment using one donor (each condition in triplicate) showing that insulin increases capillary-like
tube  formation dose dependently. (C) Combined results of 11 experiments using 3 donors. ‡p = 0.06; *p < 0.01; **p < 0.001 compared with control (C).
Fig. 2. Insulin receptor expression within human atherosclerotic plaque. Representative photomicrographs of insulin receptor expression (IR), in brown, in human atheroscle-
rotic  plaque. (A) Numerous IR positive microvessels within a foam cell rich area of the lipid core. (B) Growth of IR positive small microvessels (SV) out of the media into the
lipid  core. The larger microvessel (LV) is IR negative. (C) Small IR positive vessels (SV) sprouting off larger vessels (LV) that are less positive for the IR.
212 K.L. Rensing et al. / Atherosclerosis 222 (2012) 208– 215
Fig. 3. Co-localization of insulin receptors with different cell type markers within human atherosclerotic plaques. The ﬁrst column shows endarterectomy specimens stained
with  Elastica-van Gieson. The white rectangles indicate from which part of the plaques the immunohistochemical images of the second column are derived. In the second
column  IR is shown in red (using Vector Red) and CD31, CD68, CD3 and SMA  are shown in blue (using Vector Blue). With use of spectral imaging individual layers were
unmixed and co-localization of the different layers is depicted in the third column. (B and C) Marked co-localization of IR with endothelium (CD31), especially on small
microvessels. (E and F) Minimal co-localization of IR with macrophages (CD68). (H and I) Hardly any co-localization of IR with T-cells (CD3). (K and L) Marked co-localization
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mf  IR with SMA  on myoﬁbroblast cells located in the intima; (N and O) No co-localiz
O)  images were taken from the media layer of atherosclerotic plaques. (E), (F), (K),
 mm;  Black bar is 0.05 mm.
hich were located in the intima (Fig. 3K and L) and not on smooth
uscle cells in the media layer (Fig. 3N and O).
.2.3. Insulin receptors are mainly present on nascent, collagen IV
egative, microvessels
We  further characterized the IR expressing microvessels within
uman atherosclerotic plaques by staining sections for collagen
V, which is considered a surrogate marker of vessel maturity as
t delineates the endothelial basement membrane. We  found that
icrovessels that expressed IRs had in general no co-expression of of IR with SMA on smooth muscle cells in the media layer. (B), (C), (H), (I), (N), and
) images were taken from the intima layer of atherosclerotic plaques. White bar is
collagen IV. In contrast, IR negative microvessels broadly showed
clear collagen IV expression (Fig. 4).
4.3. Microvessel density within atherosclerotic plaques
4.3.1. Microvessel density is higher in atherosclerotic plaques
from DM2 patients that use insulin than in plaques from DM2
patients that use only oral glucose lowering agents.
To determine whether insulin use in DM2  patients is associated
with local angiogenesis within atherosclerotic plaques, microvessel
K.L. Rensing et al. / Atherosclerosis 222 (2012) 208– 215 213
Fig. 4. Insulin receptor expression on immature microvessels within human atherosclerotic plaques. The ﬁrst column shows representative photographs of double immu-
noenzyme staining for IR and CD34 (A and G) and IR and collagen IV (D and J). The black squares indicate from which part of the section the spectral imaging pictures in
the  second and third column are derived. (B and C) Marked co-localization of insulin receptors with endothelial cells on a small microvessel; a larger microvessel is insulin
r en IV
m dothel
o dicate
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seceptor negative. In picture (E) this small microvessel is not surrounded by collag
icrovessels in (H) and (I) that show co-localization of insulin receptors with en
verview photographs of endarterctomy specimen are depicted. The black arrows in
cale  bar in (A), (D), (G) and (J) = 0.1 mm.  Scale bar in (F) and (L) = 0.5 mm.ensity was analyzed within carotid endarterectomy specimens
btained from DM2  patients using insulin (n = 68) or oral glucose-
owering agents only (n = 97) (ATHERO-EXPRESS biobank). No
tatistically signiﬁcant differences in cardiovascular risk factors, whereas the larger microvessel has positive collagen IV staining. (H, I and K) The
ial cells are mostly not surrounded by collagen IV (K). In pictures (F) and (L), HE
 in which part of the plaque the double immunoenzyme stainings were performed.were observed between these two  groups (Table 1a). Additionally,
we did not ﬁnd statistically signiﬁcant differences in atheroscle-
rotic plaque characteristics (Table 1b). For each patient microvessel
density was  quantiﬁed by calculating the average number of
214 K.L. Rensing et al. / Atherosclero
Table 1a
Patients’ characteristics.
Oral agents
n = 97
Insulin
n = 68
p-Value
Mean age (years) 65.9 ± 9.0 67.6 ± 7.0 0.17
Gender (% male) 67 69 0.78
Mean BMI  (kg/m2) 27.9 ± 4.1 27.9 ± 4.6 0.99
Treated hypertension (%) 72.2 60.6 0.12
Smoking (%) 33.7 21.2 0.09
Positive family history of CVD (%) 55.3 41.5 0.12
oral agents insulin
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Fig. 5. Microvessel density in atherosclerotic plaques from DM2  patients.
Atherosclerotic plaques from 68 DM2  patients who  use insulin and 97 DM2  patients
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Aho  do not use insulin were analyzed for the presence of microvessels. The average
icrovessel density of 3 hotspots was calculated within each plaque. *p = 0.05.
icrovessels in three hotspot areas within the plaque, as explained
n Section 2. As depicted in Fig. 5, we found a clear trend towards
n increased microvessel density in plaque tissues of insulin users
ompared with those using oral glucose lowering agents only (aver-
ge number per hotspot: 8.3 (±0.5) and 10.0 (±0.8) respectively;
edian: 7.3 (IQR 5.0–10.3) and 9.2 (IQR 6.4–11.7) respectively;
 = 0.05).
When we grouped all 165 patients into quartiles according to
heir microvessel density, we observed a linear-by-linear associa-
ion between microvessel density and the presence of intra-plaque
emorrhages (Supplemental Fig. 1). The percentage of intra-plaque
emorrhages was three times higher among patients in the highest
icrovessel density quartile compared with patients in the low-
st microvessel density quartile (p for trend < 0.01). However, we
id not ﬁnd statistically signiﬁcant differences in the percentage
f intra-plaque hemorrhages between patients using insulin and
atients using oral glucose lowering agents (29.4% versus 22.7%, = 0.33, Table 1b).
able 1b
therosclerotic plaque characteristics.
Oral agents
n = 97
Insulin
n = 68
p-Value
Plaque fenotype 0.22
Fibrous (%) 44.3 32.4
Fibro-atheromatous (%) 30.9 42.6
Atheromatous (%) 24.7 25.0
Lipid core > 40% (%) 25.8 30.9 0.47
Moderate/heavy collagen (%) 82.3 83.8 0.80
Moderate/heavy macrophages (%) 60.4 64.7 0.58
Moderate/heavy SMC 71.1 72.1 0.90
Moderate/heavy calciﬁcations 52.6 63.2 0.17
Macrophages (% of plaque area) 0.49 (0.1–1.3) 0.70 (0.2–1.2) 0.39
SMCs (% of plaque area) 2.1 (1.0–3.7) 1.4 (0.4–3.7) 0.21
Luminal thrombus (%) 45.4 45.6 0.98
Intraplaque hemorrhage (%) 22.7 29.4 0.33sis 222 (2012) 208– 215
5. Discussion
In the present study we  showed that insulin enhances capillary-
like tube formation of human microvascular endothelial cells.
Secondly, we  demonstrated that IRs are highly expressed on
endothelial cells of nascent microvessels within human atheroscle-
rotic plaques. Finally, we  found a trend towards higher intra-plaque
microvessel density among DM2  patients using insulin than among
those using only oral glucose lowering agents. These ﬁndings imply
that insulin may  stimulate angiogenesis within atherosclerotic
plaques.
The engagement of insulin signaling in angiogenesis is sup-
ported by several in vivo studies. Mice lacking IRs on their
endothelium had a profound reduction in retinal neovasculariza-
tion following hypoxia compared with control mice, indicating a
crucial role for insulin in inducing angiogenesis [26]. In line, skin
of mice injected with insulin subcutaneously for 5 days showed
longer vessels with more branches compared with skin injected
with saline [27]. Finally, in patients with progressive corneal
neovascularization, disruption of IR signaling, using antisense
oligonucleotides against insulin receptor substrate-1, resulted in
regression of corneal neovascularization [28]. We  now provide con-
sistent data to show that insulin may  also increase angiogenesis
within atherosclerotic plaques.
It has already been shown that insulin can increase tube for-
mation of endothelial cells on a two-dimensional Matrigel [15,27].
However, we used a model of angiogenic sprouting, in which
capillary-like tube formation occurs in a three-dimensional ﬁbrin
matrix and results in the formation of true lumen-like structures
[18]. This model shows similarities with sprouting of new blood
vessels at sites of chronic inﬂammation, as occurs in atheroscle-
rotic plaques. Since insulin at supraphysiological concentrations
(≥10−8 M)  also activates IGF-1R receptors [29], it could be specu-
lated whether the observed increased capillary-like tube formation
following insulin stimulation was (in part) mediated through IGF-1
receptors. However, we  also found effects of insulin at concentra-
tions that only IRs are activated (10−9 M insulin), pointing towards
a direct effect of insulin on the IR.
Subsequently, we  showed that insulin receptors are present
on endothelial cells of microvessels within human atherosclerotic
plaques. Interestingly, IRs were found to be present mainly on
those microvessels lacking collagen IV. Collagen IV is a component
of the basement membrane which is formed during maturation
of capillary-like tubes. Microvessels that do not express colla-
gen IV therefore fall into the category of nascent microvessels, as
opposed to the collagen IV positive more mature microvessels. The
increased IR expression on the endothelium of nascent microves-
sels within atherosclerotic plaques is consistent with the concept
that IRs contribute to further outgrowth of these microvessels into
atherosclerotic plaques. Since we  did not reveal such a speciﬁc dis-
tribution pattern for the IGF-1 receptor, insulin signaling is more
likely to be involved in intra-plaque angiogenesis than IGF-1 sig-
naling.
Consistent with the literature, we  found that patients with
higher intra-plaque microvessel density were more common to
have intra-plaque hemorrhages. The presence of more microvessels
within atherosclerotic plaques has been associated with increased
plaque vulnerability and is an independent predictor of future car-
diovascular events [30]. In fact, many intra-plaque microvessels
show poor endothelial integrity, with membrane blebs, intra-
cytoplasmic vacuoles, poorly formed endothelial cell junctions
and basement membrane detachment [13]. Consequently, via
these microvessels, erythrocytes and leukocytes can leak into the
atherosclerotic plaque, resulting in increased inﬂammation and
intra-plaque hemorrhage [12,31]. Together with increased release
of proteolytic enzymes and matrix breakdown this makes the
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laque more vulnerable. Although we did not ﬁnd signiﬁcant dif-
erences in the percentage of intra-plaque hemorrhages between
atients using insulin and patients using oral glucose lowering
gents only, the increased microvessel density found in patients
sing insulin can be expected to be associated with an increased
ardiovascular risk.
It should be acknowledged that insulin may  only enhance angio-
enesis, when pre-existing vessels are already present within the
laque. Since microvessels are mainly present in more advanced
laques, it could be hypothesized that insulin use might increase
ngiogenesis especially in patients with advanced atherosclerosis.
n these patients it may  be reasonable to reconsider the advantages
nd disadvantages of high insulin doses.
The present study has several limitations. Firstly, the
ndarterectomy specimens that were used for microvessel
ensity analysis were derived from a heterogenous group of DM2
atients, with different duration of diabetic disease and treatment.
his excessive variation cannot be correlated or corrected for as
arameters which could provide information about the severity
f diabetes, like HbA1c, onset of diabetes and insulin dosage are
acking.
A second limitation of our study is that we do not provide
irect evidence that insulin can enhance intra-plaque angiogen-
sis in vivo. Unfortunately, a suitable animal model in which this
uestion can be directly tested in vivo is currently lacking. In most
therosclerotic animal models intra-plaque microvessels are scarce
11] which makes it difﬁcult to assess inﬂuence of insulin on intra-
laque angiogenesis. Because in vivo imaging modalities for real
ime imaging of human plaque angiogenesis are improving, it may
ecome feasible in the future to study the effect of insulin on intra-
laque angiogenesis directly in humans by using a prospective
tudy design.
In conclusion, high insulin receptor expression on nascent
icrovessels within atherosclerotic plaques is likely to be
nvolved in stimulating intraplaque angiogenesis, and thereby links
icrovascular and macrovascular disease in type 2 diabetes. How-
ver, whether insulin therapy increases plaque vulnerability and
ubsequent cardiovascular risk needs to be assessed by future
n vivo studies.
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